Navigation Links
News brief: Long-term testicular cancer survivors at high risk for neurological side effects
Date:11/25/2009

Long-term survivors of testicular cancer who were treated with cisplatin-based chemotherapy had more severe side effects, including neurological side effects and Raynaud-like phenomena, than men who were not treated with chemotherapy, according to a new study published online November 25 in the Journal of the National Cancer Institute.

Marianne Brydy, M.D., of the Department of Oncology, Haukeland University Hospital, in Bergen, Norway, and colleagues conducted a cross-sectional study to assess the prevalence of these known side effects among long-term testicular cancer survivors in Norway according to the treatment they had received. Side effects include sensory neuropathy, tinnitus, hearing impairment, and Raynaud-like phenomena (discoloration of the hands or feet on exposure to cold).

Researchers invited 1,814 men who were treated for unilateral testicular cancer during 1980-1994 to participate in a national multicenter follow-up survey conducted during 1998-2002. A total of 1,409 participants, who were allocated to three groups based on cisplatin administration, were assessable in this study.

The researchers found that at 4-21 years after the initiation of treatment for testicular cancer, men who had received any chemotherapy had statistically significantly higher odds for increasing severity of all assessed symptoms compared with men not treated with chemotherapy. Treated men also had more hearing impairment, as measured by audiometry, particularly those who had received dose-intensive chemotherapy.

"A major aim in the treatment of testicular cancer is to minimize toxic effects without compromising the high cure rate," the authors write. "Our data favor the use of chemotherapy regimens that contain 20 mg/m2 cisplatin per day to limit ototoxicity."


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

1

GOOD

Page: 1

Related medicine news :

1. In brief: New prognostic indicator for patients with IPF
2. JNCI news brief: Improving the biomarker pipeline for early cancer detection
3. JNCI news brief: Hepatitis B virus mutations may predict risk of liver cancer
4. JNCI news brief: Breast cancer hormone receptor status and risk of a second primary tumor
5. JNCI news brief: Antibody linked to chemotherapy drug inhibits ovarian cancer in lab
6. JNCI news brief: High serum insulin levels and risk of prostate cancer
7. JNCI news brief: Surgeon training found effective in breast cancer sentinel lymph node trial
8. JNCI news brief: Melanosome dynamics and sensitivity of melanoma cells to chemotherapy
9. JNCI news brief: STD confirmed to be associated with increased risk of prostate cancer
10. News brief: Effects of aspirin and folic acid on inflammation markers for colorectal adenomas
11. News brief: Estrogen receptor-alpha, breast cancer patients and tamoxifen response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... a study in 2012 suggested a cancer drug ... with Alzheimer,s disease, three groups of researchers now ... findings. The teams said their research could ... drug involved in the study, bexarotene (Targretin), has ... pancreatitis, headaches, fatigue, weight gain, depression, nausea, vomiting, ...
(Date:5/23/2013)... Emory Vaccine Center have shown that an immune regulatory ... in mice against viral infections. , The results are ... "Our findings highlight how IL-21 could be important in ... Ur Rasheed Mohammed, PhD, the first author of the ... of the Emory Vaccine Center and a Georgia Research ...
(Date:5/23/2013)... Chicago, IL (PRWEB) May 23, 2013 ... of comprehensive solutions and educational resources for the ... today that it is opening its first global ... in the Philippines in August. This new world-class ... the best of Western evidence-based practices to treat ...
(Date:5/23/2013)... 23, 2013 Six innovative research projects ... by Lyme Research Alliance, the nation's largest private nonprofit funder ... studies focus on the epidemiology of, and treatment and ... “LRA is proud to support the innovative research being ... men and women in the field today,” said Harriet ...
(Date:5/23/2013)... researchers examining outcomes for advanced heart-failure patients over ... with the increased availability and use of new ... death, caused by the rapid onset of severe ... However, the team found that even today, with ... more than three years after being diagnosed with ...
Breaking Medicine News(10 mins):Health News:Scientists Can't Replicate Surprising Finding on Alzheimer's Treatment 2Health News:Vaccine blackjack: IL-21 critical to fight against viral infections 2Health News:Special Learning, Inc. to Expand its Services for Individuals with Special Needs with Opening of New Special Education School in the Philippines 2Health News:Special Learning, Inc. to Expand its Services for Individuals with Special Needs with Opening of New Special Education School in the Philippines 3Health News:Six Investigators Awarded Lyme Research Alliance Grants 2Health News:Six Investigators Awarded Lyme Research Alliance Grants 3Health News:Six Investigators Awarded Lyme Research Alliance Grants 4Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 2Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 3
... For immediate release -- Sept. 22, 2011 (Toronto) -- A ... recommends a public health approach to cannabis - including evidence-based ... that result from the use of cannabis. Led ... (Simon Fraser University, Vancouver) Dr. Benedikt Fischer, the study is ...
... class of medicines commonly given for pain -- were associated ... 3,061 adults, aged 65 to 94, e-published in advance of ... . The study from researchers at Group Health Research Institute ... which are drugs generally given for insomnia and anxiety, did ...
... 22 (HealthDay News) -- There were 134 waterborne disease ... in the United States in 2007-08, and 36 outbreaks ... released Thursday. The 134 recreational water illness outbreaks ... in 38 states and Puerto Rico, caused at least ...
... , THURSDAY, Sept. 22 (HealthDay News) -- Almost 7 percent of ... hospitalized within 30 days of the procedure, a new study indicates. ... who do not get prostate biopsies can expect to be hospitalized, ... Journal of Urology . "The overall hospitalization rate is about ...
... , THURSDAY, Sept. 22 (HealthDay News) -- Over-the-counter asthma ... layer, will not be made or sold after Dec. ... The sole product affected is Primatene Mist, marketed ... inhaler approved by the FDA to be sold without ...
... - The University of Kentucky,s Dr. Susanne Arnold and colleagues ... study potential environmental reasons for the high lung cancer rates ... three years and the study began on Sept. 15. ... but counties in the southeastern portion of the state ...
Cached Medicine News:Health News:New study proposes public health guidelines to reduce the harms from cannabis use 2Health News:New study proposes public health guidelines to reduce the harms from cannabis use 3Health News:Opioids linked to higher risk of pneumonia in older adults 2Health News:Infections Linked to Swimming, Drinking Water: CDC 2Health News:In Older Men, Prostate Biopsies Can Raise Risk of Hospitalization 2Health News:In Older Men, Prostate Biopsies Can Raise Risk of Hospitalization 3Health News:Asthma Inhaler Primatene Mist Going Off the Market 2Health News:Lung cancer research team awarded $1.43 million to study cancer in Eastern Kentucky 2Health News:Lung cancer research team awarded $1.43 million to study cancer in Eastern Kentucky 3
(Date:5/23/2013)... 23, 2013  Inhibikase Therapeutics, Inc., an emerging ... it will present new results on its antiviral ... sponsored by the PML Consortium (composed of Pfizer, ... (JCV) is the causative agent of Progressive Multifocal ... in an extended release formulation, can clear JC ...
(Date:5/23/2013)... 23, 2013 InspireMD, Inc. ... leader in embolic protection stents, today announced new ... ST Elevation Reperfusion) trial demonstrating that the MGuard ... drug eluting stents in all-cause mortality in ST ... the trial were presented at the InspireMD STEMI ...
(Date:5/23/2013)... and PARIS , May 23, ... a leading developer and manufacturer of precision guided therapy ... coronary and peripheral vascular disease, today announced preliminary results ... I ndependent S tenosis E valuation) ... trial session at EuroPCR 2013. These prospective results confirm ...
Breaking Medicine Technology:Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 2Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 3Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 4Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 5
... BAY, Wis., Sept. 7, 2011 ... solutions to hospitals, IDNs, healthcare systems and clinics, ... of the Centers for Medicare & Medicaid Services ... Medical Documentation (esMD).  (Logo: http://photos.prnewswire.com/prnh/20110907/PH63482LOGO) ...
... 7, 2011 As NFL coaches and players face a ... one team,s preparation will be gaining a competitive edge as ... season. Today, Polar USA and the Atlanta Falcons announced that ... "Official Heart Rate Training System" of the Atlanta Falcons. ...
Cached Medicine Technology:IOD to Enter Testing Phase in CMS esMD Pilot Program 2Polar Team2 Pro Set Solution Is Official Heart Rate Training System for the Atlanta Falcons 2Polar Team2 Pro Set Solution Is Official Heart Rate Training System for the Atlanta Falcons 3
... multichannel pipettes speed up ... into microplates, with super ... volumes. The improved ergonomic ... multichannels, combined with super ...
... The Research pro Electronic Pipette is ... the laboratory. Its easy-to-follow display, ergonomically-placed operating ... pipetting, dispensing, reverse pipetting and diluting make ... the simple functions of a manual pipette ...
The Biopette E has a comfortable, ergonomic design. Fully motorized piston drive. Virtually eliminates pipetting forces. User-friendly operator interface. Simple, precise volume setting. Rechargelabl...
... best value in high performance electronic pipetting!, ... design reduce hand fatigue and strain , ... ejector , Color coding for easy volume ... greater performance use Hamilton AdvanTip Low Retention ...
Medicine Products: